The Pharma Data

AUGUST 20, 2020

Companies such as AstraZeneca, Sanofi and Eli Lilly have managed to keep business under the aggressive procurement program, but they had to live with major discounts. . It’s not a completely unforeseen shift, though. Pfizer’s established drugs business started showing a decline in China back in April 2019.

Research Analyst 52

Research Analyst Medicine Pharma Companies Marketing 52

Pharmaceutical Technology

MARCH 17, 2023

Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal research analyst, at a recent webinar on the same topic. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies.

Marketing 257

Marketing Drugs Research Analyst Manufacturing 257

Roots Analysis

JANUARY 27, 2025

Further, it has been observed that many pharma companies are directing their efforts towards introducing subcutaneous versions of their drugs by re-engineering and reformulating products that were initially developed for delivery via the intravenous route.

Marketing 40

Marketing Drug Delivery Development Protein 40